
|Articles|May 1, 2014
- BioPharm International-05-01-2014
- Volume 27
- Issue 5
Aseptic Valve Range Increases Sterility
Aseptic Valve Range Increases Sterility
Advertisement
ChargePoint AseptiSafe by ChargePoint Technology is designed to transport aseptic products or components. The valve range consists of two iterations capable of eliminating the ‘Ring of Concern’ through different methods to achieve sterility. ChargePoint AseptiSafe uses a steam-in-place process that ensures the sterilization of the internal surfaces of the valve together with the Ring of Concern. In addition, ChargePoint Aseptisafe bio uses a fast gassing system that sterilizes the valve interface in approximately six minutes.
Articles in this issue
over 12 years ago
Accelerated Stability Modelingover 12 years ago
Demand for New Vaccines Spurs Innovationover 12 years ago
Standardizing Practices for Disposablesover 12 years ago
Clinical Syringe Packages Increase Productivityover 12 years ago
Linking Drug Shortages and Quality Metricsover 12 years ago
Improving Protein Expression with Novel Systemsover 12 years ago
Integrated Single-Use Sterile and SIP Connector Provide Flexibilityover 12 years ago
India's Developing Market Offers OpportunitiesAdvertisement
Related to this article

Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.

Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.

Galinpepimut-S maintenance extended median overall survival to 24.0 vs 14.7 months in transplant-ineligible AML patients in second or later remission.

Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.

Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.
Advertisement
Advertisement
Trending on BioPharm International
1
Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach
2
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
3
SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial
4
AbbVie and DISCO Partner on AND-Gated Bispecifics Designed to Recognize Tumor-Selective Protein Pairs
5


